Abstract
Benzamide derivatives are known as antipsychotic and antiemetic drugs. Owing to its neurotropic characteristic this class of compounds was found useful for imaging melanoma and melanoma metastases. [123I]BZA (N-(2- diethylaminoethyl)-4-[123I]iodobenzamide) was the first example which was clinically applied as an imaging agent demonstrating high tumor uptake. This finding initiated research efforts to further improve the affinity and pharmacological properties of this agent. In order to optimize the use of these molecules with respect to costs and wide spread distribution, 99mTc labeled benzamides have been developed. Indeed, several 99mTc complexes were found suitable for melanoma imaging; however, they were less eligible than radioiodinated benzamides. Besides their use as radiotracers benzamides have been evaluated for magnetic resonance imaging. Molecular imaging with paramagnetic metal contrast agents for magnetic resonance tomography (MRT) is hampered by the inferior sensitivity of MRT. Biochemical trapping was thought to overcome this problem using the polyamine transporter of melanoma cells. One of the neutral, DTPA based Gd complexes comprising 2-(diethylamino)ethylamine and bis-(2-aminoethyl)amine in the side chain led to intracellular uptake values well above the MRI detection limit. An overview about benzamides used for molecular imaging and as transporters for cytostatic agents as well as inhibitors for histone deacetylases concludes this review, demonstrating that benzamide derivatives represent a versatile class of compounds leading to novel imaging and therapeutic agents.
Keywords: Melanoma imaging, targeted tumor therapy, radioiodinated benzamides, 99mTc complexes, Gd complexes, MRI contrast agents, anticancer drugs, HDAC inhibitors
Current Medicinal Chemistry
Title: Benzamides as Melanotropic Carriers for Radioisotopes, Metals, Cytotoxic Agents and as Enzyme Inhibitors
Volume: 16 Issue: 17
Author(s): D. Oltmanns, M. Eisenhut, W. Mier and U. Haberkorn
Affiliation:
Keywords: Melanoma imaging, targeted tumor therapy, radioiodinated benzamides, 99mTc complexes, Gd complexes, MRI contrast agents, anticancer drugs, HDAC inhibitors
Abstract: Benzamide derivatives are known as antipsychotic and antiemetic drugs. Owing to its neurotropic characteristic this class of compounds was found useful for imaging melanoma and melanoma metastases. [123I]BZA (N-(2- diethylaminoethyl)-4-[123I]iodobenzamide) was the first example which was clinically applied as an imaging agent demonstrating high tumor uptake. This finding initiated research efforts to further improve the affinity and pharmacological properties of this agent. In order to optimize the use of these molecules with respect to costs and wide spread distribution, 99mTc labeled benzamides have been developed. Indeed, several 99mTc complexes were found suitable for melanoma imaging; however, they were less eligible than radioiodinated benzamides. Besides their use as radiotracers benzamides have been evaluated for magnetic resonance imaging. Molecular imaging with paramagnetic metal contrast agents for magnetic resonance tomography (MRT) is hampered by the inferior sensitivity of MRT. Biochemical trapping was thought to overcome this problem using the polyamine transporter of melanoma cells. One of the neutral, DTPA based Gd complexes comprising 2-(diethylamino)ethylamine and bis-(2-aminoethyl)amine in the side chain led to intracellular uptake values well above the MRI detection limit. An overview about benzamides used for molecular imaging and as transporters for cytostatic agents as well as inhibitors for histone deacetylases concludes this review, demonstrating that benzamide derivatives represent a versatile class of compounds leading to novel imaging and therapeutic agents.
Export Options
About this article
Cite this article as:
Oltmanns D., Eisenhut M., Mier W. and Haberkorn U., Benzamides as Melanotropic Carriers for Radioisotopes, Metals, Cytotoxic Agents and as Enzyme Inhibitors, Current Medicinal Chemistry 2009; 16 (17) . https://dx.doi.org/10.2174/092986709788612684
DOI https://dx.doi.org/10.2174/092986709788612684 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mass Spectrometry-Based Strategies for Screening of Bioactive Natural Products
Combinatorial Chemistry & High Throughput Screening A Systematic SAR Study of C10 Modified Paclitaxel Analogues Using a Combinatorial Approach
Combinatorial Chemistry & High Throughput Screening Recommendations for Severe Hypertriglyceridemia Treatment, are there New Strategies?
Current Vascular Pharmacology The Renin Angiotensin System in the Regulation of Angiogenesis
Current Pharmaceutical Design Anti-Angiogenic Therapy: Strategies to Develop Potent VEGFR-2 Tyrosine Kinase Inhibitors and Future Prospect
Current Medicinal Chemistry Inhibition of Melanogenesis by Some Well-Known Polyphenolics: A Review
Current Pharmaceutical Biotechnology The Emerging Role of Large Immunophilin FK506 Binding Protein 51 in Cancer
Current Medicinal Chemistry Melatonin, Immune Function and Cancer
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Topotecan and Irinotecan in the Treatment of Pediatric Solid Tumors
Current Pediatric Reviews Proteochemometrics for the Prediction of Binding to the MHC Proteins
Letters in Drug Design & Discovery Role of Focal Adhesion Kinase in Human Cancer: A Potential Target for Drug Discovery
Anti-Cancer Agents in Medicinal Chemistry Epigenetics and Periodontal Disease: Hope to Tame the Untameable
Current Gene Therapy Bioactive Albumin-Based Carriers for Tumour Chemotherapy
Current Cancer Drug Targets Circulating Tumor Cells (CTCs) as a Liquid Biopsy Material and Drug Target
Current Drug Targets Chromatin Modification and Senescence
Current Pharmaceutical Design A New Era of Immunotherapy in Prostate Cancer
Current Molecular Pharmacology Drug Delivery to the Back of the Eye Following Topical Administration: An Update on Research and Patenting Activity
Recent Patents on Drug Delivery & Formulation Heterologous Virus-Like-Particles: Recombinant Nanosystems as Versatile Antigen Delivery Devices for Immune Intervention
Current Nanoscience Targeted Therapy for Brain Tumours: Role of PARP Inhibitors
Current Cancer Drug Targets Nucleic Acid-based Technologies in Therapy of Malignant Gliomas
Current Pharmaceutical Biotechnology